Effect of the preparation Ingavirin® (imidazolyl ethanamide pentandioic acid) on the interferon status of cells under conditions of viral infection


Cite item

Full Text

Abstract

Ingavirin® (imidazolyl ethanamide pentandioic acid) is an original antiviral drug, which is used in Russia for treatment and profilaxis of influenza and other acute viral infections. We confirmed that imidazolyl ethanamide pentandioic acid (IEPA), not being interferon inducer itself, enhances synthesis of both interferon-a/fi receptors (IFNAR) to interferone and cell sensitivity to interferone signalling, which was suppressed by NS1 protein - pathogen factor of influenza virus. IEPA is able to promote antiviral effector proteins PKR and MxA in infected cells, in opposition to interferon system suppression by influenza virus. Theoretical ground of clinical efficacy of Ingavirine® could be confirmed by obtained data of influence to innate immune system during viral infection.

About the authors

Thomas Aschacher

Medical University of Vienna

Отделение хирургии Waehringer Guertel 18-20, Vienna, Austria

Artem Krokhin

Medical University of Vienna

Отделение хирургии Waehringer Guertel 18-20, Vienna, Austria

Irina Kuznetsova

Medical University of Vienna

Отделение хирургии Waehringer Guertel 18-20, Vienna, Austria

Johannes Langle

Medical University of Vienna

Отделение хирургии Waehringer Guertel 18-20, Vienna, Austria

Vladimir Nebolsin

LLC «Pharmenterprises»

86, building 5, Vernadskogo Prospect, Moscow, 119571, Russian Federation

Andrey Egorov

Medical University of Vienna

Email: aevirol@gmail.com
PhD Waehringer Guertel 18-20, Vienna, Austria

Michael Bergmann

Medical University of Vienna

Отделение хирургии Waehringer Guertel 18-20, Vienna, Austria

References

  1. Bouvier N.M., Palese P. The biology of influenza viruses. Vaccine. 2008; 26 (Suppl. 4):D49-53. PubMed PMID: 19230160; PubMed Central PMCID: PMC3074182.
  2. Samson M., Pizzorno A., Abed Y., Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013; 98(2): 174-85. doi: 10.1016/j.antiviral.2013.03.014. PubMed PMID: 23523943.
  3. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. WHO Guidelines Approved by the Guidelines Review Committee. Geneva; 2010.
  4. Little K. et al. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015; 20(45). doi: 10.2807/1560-7917.ES.2015.20.45.30060
  5. Takahashi E., Kataoka K., Fujii K., Chida J., Mizuno D., Fukui M. et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 2010; 12(10): 778-83. doi: 10.1016/j.micinf.2010.04.013. PubMed PMID: 20452454.
  6. Shinahara W., Takahashi E., Sawabuchi T., Arai M., Hirotsu N., Takasaki Y. et al. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces reinfection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One. 2013; 8(7): e70060. doi: 10.1371/journal.pone.0070060. PubMed PMID: 23875018; PubMed Central PMCID: PMCPMC3714257.
  7. Ершов Ф.И., Наровлянский А.Н. Использование индукторов интерферона при вирусных инфекциях. Вопр. вирусол. 2015; 60(2): 5-10.
  8. Trinchieri G. Type I interferon: friend or foe? J. Exp. Med. 2010; 207(10): 2053-63. doi: 10.1084/jem.20101664. PubMed PMID: 20837696; PubMed Central PMCID: PMCPMC2947062.
  9. Davidson S., Crotta S., McCabe T.M., Wack A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun. 2014; 5: 3864. doi: 10.1038/ncomms4864. PubMed PMID: 24844667; PubMed Central PMCID: PMCPMC4033792.
  10. Шульдяков А.А., Ляпина Е.П., Кузнецов В.И., Зрячкин Н.И., Ситников И.Г., Перминова О.А. и др. Новые возможности терапии острых респираторных вирусных инфекций у детей. Вопросы практической педиатрии. 2015; 10(5): 21-8.
  11. Геппе Н.А., Рейхарт Д.В., Небольсин В.Е., Голубев А.В., Арнаутов В.С. Оценка эффективности и безопасности препарата Ингавирин®: клинические результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового исследования III фазы по оценке клинической эффективности и безопасности препарата Ингавирин®, в суточной дозе 60 мг, однократно, для лечения гриппа и других ОРВИ у детей в возрасте 7-12 лет. Участковый педиатр. 2015; (4).
  12. Колобухина Л.В., Меркулова Л.Н., Григорян С.С., Щелканов М.Ю., Оспельникова Т.П., Гусева О.А. и др. Эффективность и безопасность препарата Ингавирин® в лечении гриппа и других ОРВИ у взрослых. Справочник поликлинического врача. 2010; (9).
  13. Levy D.E., Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 2001; 12(2-3): 143-56. PubMed PMID: 11325598.
  14. Ferko B., Stasakova J., Romanova J., Kittel C., Sereinig S., Katinger H. et al. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J. Virol. 2004; 78(23): 13037-45. doi: 10.1128/JVI.78.23.13037-13045.2004. PubMed PMID: 15542655; PubMed Central PMCID: PMCPMC524997.
  15. Stasakova J., Ferko B., Kittel C., Sereinig S., Romanova J., Katinger H. et al. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J. Gen. Virol. 2005; 86(Pt 1): 185-95. doi: 10.1099/vir.0.80422-0. PubMed PMID: 15604446.
  16. Hale B.G., Randall R.E., Ortin J., Jackson D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008; 89(Pt 10): 2359-76. doi: 10.1099/vir.0.2008/004606-0. PubMed PMID: 18796704.
  17. Geiss G.K., Salvatore M., Tumpey T.M., Carter V.S., Wang X., Basler C.F. et al. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc. Natl. Acad. Sci. USA. 2002; 99(16): 10736-41. doi: 10.1073/pnas.112338099. PubMed PMID: 12149435; PubMed Central PMCID: PMCPMC125029.
  18. Egorov A., Brandt S., Sereinig S., Romanova J., Ferko B., Katinger D. et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 1998; 72(8): 6437-41. PubMed PMID: 9658085; PubMed Central PMCID: PMCPMC109801.
  19. Garcia-Sastre A., Egorov A., Matassov D., Brandt S., Levy D.E., Durbin J.E. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998; 252(2): 324-30. PubMed PMID: 9878611.
  20. Haller O., Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J. Interferon Cytokine Res. 2011; 31(1): 79-87. doi: 10.1089/jir.2010.0076. PubMed PMID: 21166595.
  21. Horvath C.M. The Jak-STAT pathway stimulated by interferon alpha or interferon beta. Sci. STKE. 2004; 2004(260): tr10. doi: 10.1126/stke.2602004tr10. PubMed PMID: 15561979.
  22. de Weerd N.A., Samarajiwa S.A., Hertzog P.J. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 2007; 282(28): 20053-7. doi: 10.1074/jbc.R700006200. PubMed PMID: 17502368.
  23. Колобухина Л.В., Меркулова Л.Н., Щелканов М.Ю., Бурцева Е.И., Лаврищева В.В., Самохвалов Е.И. и др. Пандемический грипп в России: отличительные особенности клинического течения и отсутствие ранней этиотропной терапии как фактор риска развития тяжелых форм заболевания. Тер. арх. 2011; (9): 48-53.
  24. Колобухина Л.В., Щелканов М.Ю., Меркулова Л.Н., Базарова М.В., Бурцева Е.И., Самохвалов Е.И. и др. Этиотропная терапия гриппа: уроки последней пандемии. Вестн. РАМН. 2011; (5): 35-40.
  25. Шульдяков А.А., Ляпина Е.П., Кузнецов В.И. Современные принципы химиопрофилактики острых респираторных вирусных инфекций. Тер. арх. 2013; (11): 27-33.

Copyright (c) 2016 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies